



Press Release / Press Release

For Immediate Release

CYTOMICS SYSTEMS RECEIVES A €2.1M GRANT FROM OSEO INNOVATION

Gif-sur-Yvette (France) – October 12, 2007 - CYTOMICS SYSTEMS, a privately-held development stage company with proprietary expertise in protein degradation pathways, today announced that it has secured a €2.1M grant for OSEO Innovation to support its on-going program in the anti-fungal area, a 3.5 billion euros market. It is the second grant that the Company receives from this State-owned agency.

Bernard Cambou, PhD., Chairman of the Management Board commented : *"It is extremely rewarding to have the continuous support from OSEO Innovation. It is well known that they are extremely selective in their selection of candidate awardees. The continuous progress in our quest for improved anti-fungal agents against life-threatening systemic infections have provided us with the means to achieve a significant financial award from OSEO Innovation."*

CYTOMICS's approach utilizes a novel proprietary target that is only present in fungi. Using its *UbiScreen*[®] screening platform the Company has identified molecules that inhibit the degradation of this target protein. Such inhibition is selectively lethal to a wide spectrum of clinically-relevant fungi. *"We have achieved a significant milestone in this program, our challenge now is to turn the opportunities into druggable and clinically safe drug candidates and novel treatment modality"*, added Bernard Cambou.

"In 2003, Cytomics Systems was awarded a first grant to help establish its proprietary UbiScreen[®] platform. This successful endeavor has led to this larger grant from OSEO Innovation. The current financing reflects our willingness to participate in the next phase of growth of the company on a risk sharing basis", said Mr François-Henri Sahakian, Business Manager at OSEO Innovation and who oversees CYTOMICS SYSTEMS in their company portfolio.

Dr. Thierry Hercend, MD, PhD and Chairman of the Supervisory Board of Cytomics Systems commented : *"We are pleased to receiving further financial support from OSEO Innovation. Thanks to the continuous support of its venture investors and to the substantial contribution from the Agency, the Company is well funded and positioned to achieve its short and middle term objectives"*.

About CYTOMICS SYSTEMS

CYTOMICS SYSTEMS is a biopharmaceutical company pioneering the discovery and development of drugs that control the degradation of proteins, to treat major human diseases such as cancer and fungal infections. The Company was founded by Dominique Thomas, PhD, Director of Research at the CNRS Center for Molecular Genetics, and internationally recognized for his work in the field of the Ubiquitin-Proteasome pathway for protein degradation.

The Company has developed an innovative high-throughput screening technology, *UbiScreen*[®], for the discovery of new therapeutic molecules controlling the degradation of target proteins. *CYTOMICS SYSTEMS* has used this technology to target fungal infections. Another drug development program in the field of oncology has led to the selection of very promising molecules.

The company is based in Gif-sur-Yvette (France) and has 22 employees including 9 PhDs.
(www.cytomics.fr)

Contacts

CYTOMICS SYSTEMS

Erwan MARTIN, CFO

Tél. : +33 (0)1 69 82 42 46

E-mail : emartin@cytomics.fr

MILESTONES – Press Relations

Bruno ARABIAN

Tél. : +33 (0)1 70 08 04 13 / +33 (0)6 87 88 47 26

E-mail : milestones@milestones-fr.com